GlassScriptPhysician profile
Lee C Pederson
NPI 1083690622
$2,010.37
in general payments reported to CMS, 2019-2025
28 companies · $41.43 in 2025
The $41.43 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.63 · 2020: $12.35 · 2022: $277 · 2023: $232 · 2024: $1,405 · 2025: $41.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Travel and Lodging: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.89 |
| Travel and Lodging | $579.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,264.81 | 2024 | |
| Abbvie INC. | $87.01 | 2022 | |
| Amneal Pharmaceuticals LLC | $64.67 | 2022-2023 | Unithroid |
| Abbott Laboratories | $55.26 | 2024 | Esprit |
| Merck Sharp & Dohme LLC | $47.47 | 2022 | |
| Surmodics, INC. | $40.80 | 2023 | Pounce Thrombectomy System |
| Smith+Nephew, INC. | $37.09 | 2022-2023 | Stravix, Grafix Pl |
| Medtronic, INC. | $35.65 | 2023-2024 | Pteye Parathyroid Detection System, Plasmablade(Tm) |
| Solventum Corporation | $35.29 | 2024 | Activ.A.C. |
| Endologix LLC | $30.89 | 2023 | Afx2 Bifurcated Endograft System, Ovation Ix Iliac Stent Graft |
| Vertex Pharmaceuticals Incorporated | $27.80 | 2024 | |
| Cordis US Corp. | $25.01 | 2025 | Mynx Control |
| Triad Life Sciences INC. | $22.13 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.06 | 2022 | |
| Sanara Medtech INC. | $21.41 | 2023 | Celleraterx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $19.88 | 2023 | Korlym |
| Lemaitre Vascular, INC. | $18.73 | 2023 | Hydro Lemaitre Valvulotome |
| Allergan, INC. | $18.43 | 2019 | |
| Innocoll Pharmaceuticals Limited | $18.17 | 2022 | |
| Pfizer INC. | $16.89 | 2022 | |
| Davol INC. | $16.42 | 2025 | |
| Mozarc Medical US LLC | $15.92 | 2023 | Argyle |
| Teleflex LLC | $14.06 | 2023 | Weck |
| Biom'Up France Sas | $12.35 | 2020 | |
| Ibsa Pharma INC. | $12.02 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $11.18 | 2019 | |
| Cardiovascular Systems INC. | $9.99 | 2022 | |
| Kerecis Limited | $8.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Pederson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.